drugset

drugset / Trial / NCT00908778

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

NCT00908778 ↗

Phase 3 Unknown 160 enrolled Vitreoretinal Technologies, Inc.

RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.

Timeline

Start: 2008-10
Primary completion: 2010-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vitreosolve	Unknown	—	Intravitreal

Indications